Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.
暂无分享,去创建一个
U. Mellqvist | M. Dimopoulos | Shaji K. Kumar | X. Leleu | K. Ramasamy | R. Fenk | M. Levin | F. Schjesvold | V. Doronin | H. Quach | A. Pompa | M. Darif | Cindy H. Lee | H. Sati | J. Du | R. Labotka | O. Vinogradova | A. Vorog | G. Yolanda